Antimicrobial resistance to linezolid

Clinical Infectious Diseases

Volumn 39, Issue 7, 2004, Pages 1010-1015

  Meka, Venkata G ^a   Gold, Howard S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; OXAZOLIDINONE DERIVATIVE; RNA 23S;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; CLINICAL TRIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE COCCI; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; HUMANS; OXAZOLIDINONES; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 4744364598     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/423841     Document Type: Article

References (38)

1. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138:135-42.
2. Food and Drug Administration. FDA approves Zyvox, the first antimicrobial drug in a new class [presentation paper]. 18 April 2000. Available at: http://www.fda.gov/bbs/topics/ANSWERS/ANS01010.html. Accessed 10 May 2004.
3. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40:839-45.
4. Buysse JM, Demyan WF, Dunyak DS, Stapert D, Hamel JC, Ford CW. Mutation of the AcrAB antibiotic efflux pump in Escherichia coli confers susceptibility to oxazolidinone antibiotics [abstract C42]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1996:41.
5. Eustice DC, Feldman PA, Zajac I, Slee AM. Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis. Antimicrob Agents Chemother 1988; 32:1218-22.
6. Lin AH, Murray RW, Vidmar TJ, Marotti KR. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother 1997; 41:2127-31.
7. Matassova NB, Rodnina MV, Endermann R, et al. Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA 1999; 5:939-46.
8. Shinabarger DL, Marotti KR, Murray RW, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997; 41:2132-6.
9. Fines M, Leclercq R. Activity of linezolid against gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors. J Antimicrob Chemother 2000; 45:797-802.
10. Klappenbach JA, Saxman PR, Cole JR, Schmidt TM. rrndb: the Ribosomal RNA Operon Copy Number Database. Nucleic Acids Res 2001; 29:181-4.
11. Xiong L, Kloss P, Douthwaite S, et al. Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action. J Bacteriol 2000; 182:5325-31.
12. Mutnick AH, Biedenbach DJ, Turnidge JD, Jones RN. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis 2002; 43:65-73.
13. Swaney SM, Shinabarger DL, Schaadt RD, Bock JH, Slightom JL, Zurenko GE. Oxazolidinone resistance is associated with a mutation in the peptidyl transferase region of 23S rRNA [abstract C-104]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 1998:98-9.
14. Prystowsky J, Siddiqui F, Chosay J, et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 2001; 45:2154-6.
15. Kloss P, Xiong L, Shinabarger DL, Mankin AS. Resistance mutations in 23S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol 1999; 294:93-101.
16. Sander P, Belova L, Kidan YG, Pfister P, Mankin AS, Bottger EC. Ribosomal and non-ribosomal resistance to oxazolidinones: species-specific idiosyncrasy of ribosomal alterations. Mol Microbiol 2002; 46: 1295-304.
17. Howe RA, Noel A, Bowker KE, Enne VI, Walsh TR, MacGowan AP. Emergence of linezolid (LIN) resistance in Staphylococcus aureus can be associated with loss of erythromycin (ERY) resistance [abstract C1-1608]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:75.
18. Zurenko GE, Todd WM, Hafkin B, et al. Development of linezolid-resistant Enterococcusfaecium in two Compassionate Use Program patients treated with linezolid [abstract 848]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1999:118.
19. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcusfaecium resistant to linezolid [letter]. Lancet 2001; 357:1179.
20. Ruggero KA, Schroeder LK, Schreckenberger PC, Mankin AS, Quinn JP. Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis: evidence for a gene dosage effect on linezolid MICs. Diagn Microbiol Infect Dis 2003; 47:511-3.
21. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant vancomycin-resistant Enterococcus faecium. N Engl J Med 2002; 346: 867-9.
22. Pai MP, Rodvold KA, Schreckenberger PC, Gonzales RD, Petrolatti JM, Quinn JP. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2002; 35:1269-72.
23. Marshall SH, Donskey CJ, Hutton-Thomas R, Salata RA, Rice LB. Gene dosage and linezolid resistance in Enterococcusfaecium and Enterococcus faecalis. Antimicrob Agents Chemother 2002; 46:3334-6.
24. Lobritz M, Hutton-Thomas R, Marshall S, Rice LB. Recombination proficiency influences frequency and locus of mutational resistance to linezolid in Enterococcus faecalis. Antimicrob Agents Chemother 2003; 47:3318-20.
25. Mazur W, Knob C, Fraimow HS. Quantification of 23S rRNA mutations and relative fitness of clinical isolates of linezolid-resistant Enterococcus faecalis [abstract C1-1607]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:75.
26. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358:207-8.
27. Pillai SK, Sakoulas G, Wennersten C, et al. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J Infect Dis 2002; 186:1603-7.
28. Wilson P, Andrews JA, Charlesworth R, et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 2003; 51:186-8.
29. Machado ARL, Andrade SS, Barth AL, Lutz L, Sader HS, Gales AC. The emergence of linezolid-resistance among Staphylococcus aureus from cystic fibrosis patients [abstract C2-1825]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003:144.
30. Paterson DL, Potoski BA, Kolano J, Marsh J, Pasculle AW, McCurry K. Fatal infection due to Staphylococcus aureus with decreased linezolid susceptibility [abstract K-1405]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003: 385.
31. Paterson DL, Pasculle AW, McCurry K. Linezolid: the first oxazolidinone antimicrobial [letter]. Ann Intern Med 2003; 139:863-4.
32. Meka VG, Pillai SK, Sakoulas G, et al. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis 2004; 190:311-7.
33. Mutnick AH, Enne V, Jones RN. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann Pharmacother 2003; 37:769-74.
34. Jones RN, Anderegg TR, Biedenbach DJ, Mutnick AH. First annual report from the Worldwide ZAAPS Oxazolidinone Resistance and Usage Surveillance Program (2002) [abstract C2-2172]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003:161.
35. Carsenti H, Vandenbos F, Galimand M, Pradier C, Dunais B, Dellamonica P. Emergence of linezolid (LIN) resistance in Streptococcus pneumoniae can be associated with loss of erythromycin (ERY) resistance [abstract C1-2124]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003:101.
36. Howe RA, Noel AR, Bowker KE, Bennett PM, Walsh TR, MacGowan AP. Linezolid resistance in Streptococcus pneumoniae [abstract C1-1611]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:76.
37. Paterson DL, Harrison LH, Linden PK, Pasculle AW, Muto CA. Susceptibility of vancomycin resistant Enterococcusfaecium (VRE) to quinupristin/dalfopristin (Q/D), linezolid (LZD) and daptomycin [abstract K-1409]. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2003:386.
38. Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003; 47:2775-80.